A 67-year-old female patient with postoperative recurrence of stage IV right renal cell carcinoma and multiple intracranial metastases was treated with sorafenib and sintilimab. Within 2 weeks, the patient had a fever and red spotted rash in facial, back, buttocks and limb. After 2 days, the fever completely relieved, but subcutaneous exudation appeared on the skin of both elbow joints, buttocks, and outer thighs, followed by gradual epidermal lysis and detachment with skin ulceration. After 4 days, the patient’s epidermolysis area was greater than 30% of the body surface area. The patient was diagnosed with toxic epidermal necrolysis (TEN). The adverse reaction correlation was assessed by ALDEN SCORE sheet. The adverse reaction of TEN was "likely" caused by sorafenib and sintilimab. After withdrawal and treatment, the TEN was cured. This paper explores the correlation between the TEN and the combination use of sorafenib and sintilimab and the management. This paper will provide reference for the early diagnosis and correct treatment of TEN.

1.Arora R, Pande RK, Panwar S, et al. Drug-related stevens-johnson syndrome and toxic epidermal necrolysis: a review[J]. Indian J Crit Care Med, 2021, 25(5): 575-579. DOI: 10.5005/jp-journals-10071-23826.

2.中华医学会皮肤性病学分会药物不良反应研究中心. Stevens-johnson综合征/中毒性表皮坏死松解症诊疗专家共识[J]. 中华皮肤科杂志, 2021, 54(5): 376-381. DOI: 10.35541/cjd.20201177.

3.White KD, Abe R, Ardern-Jones M, et al. SJS/TEN 2017: Building multidisciplinary networks to drive science and translation[J]. J Allergy Clin Immunol Pract, 2018, 6(1): 38-69. DOI: 10.1016/j.jaip.2017.11.023.

4.Neill BC, Seger EW, Ferguson JE, et al. SJS/TEN: a mnemonic for early clinical diagnosis of Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. Kans J Med, 2021, 14: 114-115. DOI: 10.17161/kjm.vol1414842.

5.Bastuji-Garin S, Fouchard N, Bertocchi M, et al. Scorten: a severity-of-illness score for toxic epidermal necrolysis[J]. J Invest Dermatol, 2000, 115(2): 149-153. DOI: 10.1046/j.1523-1747.2000.00061.x.

6.National Institute of Cancer. Common Terminology Criteria of Adverse Events (CTCAE) v5.0[S]. 2017: 3-146.

7.Robinson S, Saleh J, Curry J, et al. Pembrolizumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with metastatic cervical squamous cell carcinoma: a case report[J]. Am J Dermatopathol, 2020, 42(4): 292-296. DOI: 10.1097/DAD.0000000000001527.

8.Wildermuth A. Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. JAAPA, 2020, 33(8): 48-49. DOI: 10.1097/01.JAA.0000684164.28009.4a.

9.Rosen AC, Balagula Y, Raisch DW, et al. Life-threatening dermatologic adverse events in oncology[J]. Anticancer Drugs, 2014, 25(2): 225-234. DOI: 10.1097/CAD.0000000000000032.

10.Hsu DY, Brieva J, Silverberg NB, et al. Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in united states adults[J]. J Invest Dermatol, 2016, 136(7): 1387-1397. DOI: 10.1016/j.jid.2016.03.023.

11.Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The euroscar-study[J]. J Invest Dermatol, 2008, 128(1): 35-44. DOI: 10.1038/sj.jid.5701033.

12.Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis[J]. Clin Pharmacol Ther, 2010, 88(1): 60-68. DOI: 10.1038/clpt.2009.252.

13.Creamer D, Walsh SA, Dziewulski P, et al. UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016[J]. J Plast Reconstr Aesthet Surg, 2016, 69(6): e119-e153. DOI: 10.1016/j.bjps.2016.01.034.

14.高澜, 劳力民. 中毒性表皮坏死松解症病因及发病危险因素研究进展[J]. 中国麻风皮肤病杂志, 2023, 39(5): 382-386. [Gao L, Lao LM. Update of etiology and risk factors of toxic epidermal necrolysis[J]. China Journal of Leprosy and Skin Diseases, 2023, 39(5): 382-386] DOI: 10.12144/zgmfskin202305382.

15.Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions[J]. JAMA, 2014, 312(5): 525-534. DOI: 10.1001/jama.2014.7859.

16.Frey N, Jossi J, Bodmer M, et al. The epidemiology of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK[J]. J Invest Dermatol, 2017, 137(6): 1240-1247. DOI: 10.1016/j.jid.2017.01.031.

17.彭伟东, 戢太阳, 冉凤英, 等. 信迪利单抗相关皮肤不良反应文献分析[J]. 现代药物与临床, 2022, 37(11): 2616-2620. [Peng WD, Ji TY, Ran FY, et al. Literature analysis of cutaneous adverse drug reactions induced by sintilimab[J]. Drugs & Clinic, 2022, 37(11): 2616-2620.] DOI: 10.7501/j.issn.1674-5515.2022.11.034.

18.Choi MK, Woo HY, Heo J, et al. Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma[J]. Ann Dermatol, 2011, 23(Suppl 3): S404-407. DOI: 10.5021/ad.2011.23.S3.S404.

19.Abe R. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis[J]. J Dermatol, 2015, 42(1): 42-48. DOI: 10.1111/1346-8138.12674.

20.Khan Z, Hammer C, Guardino E, et al. Mechanisms of immune-related adverse events associated with immune checkpoint blockade: Using germline genetics to develop a personalized approach[J]. Genome Med, 2019, 11(1): 39. DOI: 10.1186/s13073-019-0652-8.

21.Goldinger SM, Stieger P, Meier B, et al. Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy[J]. Clin Cancer Res, 2016, 22(16): 4023-4029. DOI: 10.1158/1078-0432.CCR-15-2872.

22.Garcia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: Does early withdrawal of causative drugs decrease the risk of death?[J]. Arch Dermatol, 2000, 136(3): 323-327. DOI: 10.1001/archderm.136.3.323.

23.Thompson JA, Schneider BJ, Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(4): 387-405. DOI: 10.6004/jnccn.2022.0020.